Three Seasons Wealth LLC Makes New $723,000 Investment in Eli Lilly and Company (NYSE:LLY)

Three Seasons Wealth LLC bought a new stake in Eli Lilly and Company (NYSE:LLY - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 937 shares of the company's stock, valued at approximately $723,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Highline Wealth Partners LLC raised its position in shares of Eli Lilly and Company by 80.0% in the fourth quarter. Highline Wealth Partners LLC now owns 45 shares of the company's stock valued at $35,000 after purchasing an additional 20 shares during the period. FPC Investment Advisory Inc. raised its holdings in Eli Lilly and Company by 358.3% during the 4th quarter. FPC Investment Advisory Inc. now owns 55 shares of the company's stock valued at $45,000 after acquiring an additional 43 shares during the period. Prudent Man Investment Management Inc. purchased a new stake in shares of Eli Lilly and Company during the fourth quarter worth $48,000. Compass Financial Services Inc bought a new position in shares of Eli Lilly and Company in the fourth quarter worth $50,000. Finally, Fiduciary Advisors Inc. purchased a new position in shares of Eli Lilly and Company in the fourth quarter valued at $58,000. 82.53% of the stock is owned by institutional investors.

Insider Activity at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the business's stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the sale, the chief accounting officer now owns 5,840 shares in the company, valued at approximately $4,778,521.60. The trade was a 14.62 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.13% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

LLY has been the subject of several analyst reports. Guggenheim cut their target price on Eli Lilly and Company from $973.00 to $928.00 and set a "buy" rating for the company in a research note on Monday, April 14th. The Goldman Sachs Group raised shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and reduced their price objective for the company from $892.00 to $888.00 in a research note on Tuesday, April 8th. Wells Fargo & Company increased their target price on shares of Eli Lilly and Company from $970.00 to $1,100.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 5th. Cantor Fitzgerald started coverage on shares of Eli Lilly and Company in a report on Tuesday. They issued an "overweight" rating and a $975.00 price target on the stock. Finally, Citigroup dropped their price objective on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a "buy" rating for the company in a research note on Tuesday, January 28th. Two equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. According to MarketBeat.com, Eli Lilly and Company has an average rating of "Moderate Buy" and a consensus price target of $1,017.00.

Eli Lilly and Company Trading Up 2.9 %

Shares of LLY traded up $25.21 during mid-day trading on Friday, hitting $884.94. 3,395,903 shares of the company's stock traded hands, compared to its average volume of 3,444,748. The firm has a market capitalization of $839.07 billion, a P/E ratio of 75.57, a PEG ratio of 1.40 and a beta of 0.51. The business's 50-day moving average price is $827.69 and its 200-day moving average price is $817.91. Eli Lilly and Company has a 1 year low of $677.09 and a 1 year high of $972.53. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. As a group, sell-side analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.